Fluorogenic Platform for Real-Time Imaging of Subcellular Payload Release in Antibody–Drug Conjugates

Ferran Nadal‐Bufí, Paulin Salomon, Fabio De Moliner, Kathy Sarris, Zhi Wang, Rachel Wills, Violeta L. Marin, X.y. Shi, Kaixiong Zhou, Zhongyuan Wang, Zhou Xu, Michael J. McPherson, Christopher C. Marvin, Adrian D. Hobson, Marc VendrellJournal of the American Chemical Society 2025 · DOI

TL;DR

This paper introduces a novel platform of "smart" fluorescent probes that can simultaneously track where an antibody-drug conjugate (ADC) goes inside a cell and when its therapeutic payload is released. This breakthrough allows researchers to visualize the complex journey of ADCs in real-time, paving the way for designing more effective cancer therapies.

What Problem Does This Paper Address?

Antibody-drug conjugates (ADCs) are a powerful class of cancer therapeutics designed to deliver potent drugs specifically to cancer cells, minimizing damage to healthy tissues. They work by attaching a drug to an antibody that recognizes a target on cancer cells. Once inside the cell, the ADC is processed, and the drug is released. However, understanding precisely when and where this drug release happens within the cell has been a major challenge. This is crucial because inefficient or premature drug release can reduce efficacy and increase side effects. Current methods for tracking ADCs and their payload release are often indirect, lack spatial resolution, or are not suitable for real-time live-cell imaging. This paper aims to bridge this gap by developing a tool that can visualize both the ADC's journey through the cell's endolysosomal pathway and the critical event of drug release.

Methods

The core innovation lies in the design of tandem-activated fluorogenic probes based on naphthalimide chemistry. These probes are engineered with multiple "switches" that control their fluorescence:

  • pH-sensitive groups: These groups allow the probe to emit light only in the acidic environments found in endosomes and lysosomes (pH ~4.5-6.5). This helps track the ADC's journey through these cellular compartments.
  • Enzyme-activatable quenchers (carbamate cages): These groups are designed to be cleaved by specific enzymes (like cathepsins) that are active during ADC processing. This cleavage event "uncages" the fluorophore, turning on its fluorescence and signaling payload release.

The researchers synthesized a library of 26 such naphthalimide derivatives, systematically varying the pH-sensitive amine groups. They then selected promising candidates and further modified them by incorporating intramolecular quenchers linked via dipeptide (Ala-Ala) sequences, which mimic the cleavable linkers used in many ADCs. These modified fluorophores were then conjugated to antibodies targeting tumor necrosis factor alpha (TNFα), a common target for ADCs. Live-cell imaging microscopy was performed using confocal microscopy, often in conjunction with lysosomal markers (LysoTracker Red) and cell membrane markers (CellMask Deep Red), to visualize the ADC's localization and the activation of the fluorophore. They also performed functional assays (luminescence-based reporter assays) to confirm that the fluorophore conjugation did not interfere with the ADC's ability to release its payload.

Datasets

Not discussed in the paper. The study focuses on developing and validating a new imaging platform using cell lines (HEK293 cells transfected with mTNFα and K562 GRE reporter cells) and custom-synthesized ADCs.

Key Insights and Ideas

  • Dual-activation is key: The most significant insight is the development of probes that require both acidic pH and enzymatic cleavage to become fluorescent. This provides a much more specific signal for payload release than pH-only activation, which could occur simply due to lysosomal trafficking.
  • Compact probes don't hinder function: The small size of the naphthalimide fluorophores was shown to not negatively impact the antibody's ability to bind its target receptor or the ADC's overall payload release kinetics. This is crucial for practical ADC design.
  • Lysosomal residence time matters: The study revealed that ADCs don't just need to reach lysosomes; they require a certain residence time within these acidic compartments for efficient linker cleavage and payload release. This highlights the dynamic nature of intracellular processing.
  • Payload release can be spatially nuanced: In some cases, the fluorescence signal suggesting payload release was observed in regions outside of clearly defined lysosomes, hinting at potential release mechanisms that are not solely confined to the lysosomal lumen.
  • Modular platform potential: The synthetic strategy for creating these dual-activated probes is presented as modular, suggesting it can be adapted to various ADC designs and payloads.

Key Results

  • A library of 26 pH-sensitive naphthalimide fluorophores was synthesized and characterized, with several showing significant fluorescence enhancement (up to 41.6-fold) in acidic conditions.
  • Selected pH-sensitive fluorophores were successfully conjugated to an anti-TNFα antibody (8C11), enabling visualization of receptor-mediated internalization into mTNFα-expressing cells.
  • The development of intramolecular quenchers (carbamate cages) led to a ~40-fold reduction in fluorescence, confirming their potential for OFF-to-ON signaling.
  • A dual-activated probe (A17-C-AA) requiring both acidic pH and cathepsin B activity was synthesized and demonstrated to emit fluorescence only under these specific conditions in vitro.
  • Live-cell imaging of ADCs conjugated with the dual-activated probe showed fluorescence activation occurring after 4-8 hours, correlating with lysosomal localization and indicating successful linker cleavage and payload release.
  • Functional assays confirmed that the fluorophore conjugation did not significantly alter the payload release efficacy of the ADCs compared to their non-fluorescent counterparts.

Limitations and Future Work

  • Specific enzyme dependence: While cathepsin B was used as a model enzyme, the specific enzymes involved in linker cleavage can vary between ADC designs and cell types. Future work could explore probes responsive to a broader range of relevant proteases.
  • Potential for off-target release: The observation of fluorescence signals outside of lysosomes suggests that payload release might not always be strictly confined to these organelles. Further investigation is needed to understand the mechanisms and implications of such spatially distributed release.
  • In vivo translation: While the platform is designed for live-cell imaging, its application in more complex in vivo models would be a significant next step to assess its utility for preclinical and clinical studies.
  • Broader ADC applicability: While demonstrated to be modular, extensive testing with a wider array of ADCs, including those with different antibodies, linkers, and payloads, would further validate its versatility.

Summary updated

Abstract

Antibody-drug conjugates (ADCs) represent promising therapeutic constructs to enhance the selective delivery of drugs to target cells; however, attaining precise control over the timing and location of payload release remains challenging due to the complex intracellular processes that define ADC internalization, trafficking, and linker cleavage. In this study, we present novel real-time fluorogenic probes to monitor both subcellular dynamics of ADC trafficking and payload release. We optimized a tandem molecular design of sequential pH- and enzyme-activatable naphthalimide fluorophores to (1) track their subcellular localization along the endolysosomal pathway and (2) monitor linker cleavage with OFF-to-ON fluorescence switches. Live-cell imaging microscopy revealed that fluorogenic ADCs can traffic to the lysosomes and yet require residence time in these subcellular compartments for efficient linker cleavage. Notably, the compact size of fluorogenic naphthalimides did not impair the recognition of target cell surface reporters or the kinetics of payload release. This modular platform is applicable to many ADCs and holds promise to inform their rational design for optimal release profiles and therapeutic efficacy.
BibTeX
@article{nadalbufi2025fluorogenic,
  author = {Ferran Nadal‐Bufí and Paulin Salomon and Fabio De Moliner and Kathy Sarris and Zhi Wang and Rachel Wills and Violeta L. Marin and X.Y. Shi and Kaixiong Zhou and Zhongyuan Wang and Zhou Xu and Michael J. McPherson and Christopher C. Marvin and Adrian D. Hobson and Marc Vendrell},
  title = {{Fluorogenic Platform for Real-Time Imaging of Subcellular Payload Release in Antibody–Drug Conjugates}},
  journal = {Journal of the American Chemical Society},
  year = {2025},
  doi = {10.1021/jacs.4c16842},
}
Figure